NCT06070272
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Not Yet Recruiting · Not specified · Power Life Sciences Inc. · registry updated 2023-10-06
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.
Inclusion
- Patient is at least 18 years of age
- Diagnosis of recurrent prostate cancer
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Enrolled in another research study
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Inability to provide written informed consent